Ocuphire Pharma Announces Acquisition Of Opus Genetics; Ocuphire Issued 5.2M Shares Of Its Common Stock And 14.1K Shares Of Its Convertible Preferred Stock To Existing Stockholders Of Opus Genetics; Ocuphire Will Own ~58% Of The Combined Company's Fully Diluted Capitalization, And Pre-Acquisition Stockholders Of Opus Genetics Will Own ~42% Of The Combined Company's Fully Diluted Capitalization
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma has acquired Opus Genetics, issuing 5.2 million common shares and 14.1 thousand convertible preferred shares to Opus Genetics' stockholders. Ocuphire will own 58% of the combined company, while Opus Genetics' stockholders will own 42%.
October 22, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocuphire Pharma has acquired Opus Genetics, issuing shares to Opus stockholders. Ocuphire will own 58% of the combined company, potentially impacting its stock price.
The acquisition of Opus Genetics by Ocuphire Pharma involves issuing new shares, which could lead to a positive market reaction due to the potential growth and synergies from the merger. Ocuphire will have a majority stake in the combined entity, which may enhance its market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100